100s of titles, one news app for just $10 a month.
Latest Business news:
Survivor, Bachelor in Paradise, Love Island: How Fiji is cashing in on reality TV favourites
Fiji is a small nation looking for big investment and it is working hard to make film and reality television…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
The Stats Guy: What does tourism in Australia look like now that travellers are returning?
The tourism sector is preparing for a comeback. So, what is the state of play in the sector and what…
Tech’s High-Flying Startup Scene Gets a Crushing Reality Check
Job cuts and a sour investment climate are hitting big companies like Stripe and Instacart, and may slam smaller ones…
Has crash in stablecoins slowed down sales in NFTs?
According to CrytoSlam data, so far in May, sales in NFTs stand at $2.4 billion with a total transaction of…
Fraud alert! AI identifies the four stages of a scam phone call
Australian researchers have used machine learning techniques to identify the typical four stages of fraudulent money-taking phone calls.
From analysis to good news, read the world’s best news in one place
Do Walmart and Target Have an Inventory Problem?
Ark Investing's Cathie Wood thinks so and this could be good for consumers, but maybe not investors at least in…
How an Energy Expert Triggered Vladimir Putin With One Word
Daniel Yergin was at the St. Petersburg International Economic Forum in 2013 when he got a daunting request: Could he…

Preview: Gracell Biotechnologies's Earnings

By Benzinga Insights

Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement.

Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.21.

Gracell Biotechnologies bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.03, which was followed by a 6.56% increase in the share price the next day.

Here's a look at Gracell Biotechnologies's past performance and the resulting price change:

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.33 -0.12 -0.12
EPS Actual -0.30 -0.30 -0.20 -0.25
Price Change % 6.56% 3.3% 1.71% -2.06%

Stock Performance

Shares of Gracell Biotechnologies were trading at $3.14 as of May 12. Over the last 52-week period, shares are down 73.23%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

To track all earnings releases for Gracell Biotechnologies visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.